Thrombophilic factor analysis in cirrhotic patients with portal vein thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 40, Issue 1, 2015, Pages 54-60

  Saugel, Bernd ^a,b   Lee, Marcel ^a   Feichtinger, Stephanie ^a   Hapfelmeier, Alexander ^a   Schmid, Roland M ^a   Siveke, Jens T ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Factor V Leiden mutation; JAK2 V617F mutation; Liver cirrhosis; Portal vein thrombosis; Prothrombin mutation

Indexed keywords

BLOOD CLOTTING FACTOR 5 LEIDEN; JANUS KINASE 2; PROTHROMBIN; BLOOD CLOTTING FACTOR 5; GENETIC MARKER; JAK2 PROTEIN, HUMAN;

ADULT; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; FACTOR V LEIDEN GENE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; HUMAN; JANUS KINASE 2 GENE; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DYNAMICS; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTHROMBIN GENE; AGED; BLOOD; GENETIC MARKER; GENETICS; METABOLISM; MUTATION; PATHOLOGY; PORTAL VEIN; VENOUS THROMBOSIS;

ADULT; AGED; CASE-CONTROL STUDIES; FACTOR V; FEMALE; GENETIC MARKERS; HUMANS; JANUS KINASE 2; LIVER CIRRHOSIS; MALE; MIDDLE AGED; MUTATION; PORTAL VEIN; PROTHROMBIN; VENOUS THROMBOSIS;

EID: 84933187666     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1124-z     Document Type: Article

References (26)

1. Smalberg JH, Kruip MJ, Janssen HL, Rijken DC, Leebeek FW, de Maat MP (2011) Hypercoagulability and hypofibrinolysis and risk of deep vein thrombosis and splanchnic vein thrombosis: similarities and differences. Arterioscler Thromb Vasc Biol 31(3):485–493. doi:10.1161/ATVBAHA.110.213371
2. DeLeve LD, Valla DC, Garcia-Tsao G (2009) Vascular disorders of the liver. Hepatology 49(5):1729–1764. doi:10.1002/hep.22772
3. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH (2006) Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 12(13):2115–2119
4. Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501):1945–1953. doi:10.1016/S0140-6736(05)67785-9
5. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 434(7037):1144–1148. doi:10.1038/nature03546
6. Tefferi A, Skoda R, Vardiman JW (2009) Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics. Nat Rev Clin Oncol 6(11):627–637. doi:10.1038/nrclinonc.2009.149
7. Ameziane N, Lamotte M, Lamoril J, Lebret D, Deybach JC, Kaiser T, de Prost D (2003) Combined factor V leiden (G1691A) and prothrombin (G20210A) genotyping by multiplex real-time polymerase chain reaction using fluorescent resonance energy transfer hybridization probes on the Rotor-Gene 2000. Blood Coagul Fibrinolysis 14(4):421–424
8. Sutton BC, Allen RA, Zhao ZJ, Dunn ST (2007) Detection of the JAK2V617F mutation by asymmetric PCR and melt curve analysis. Cancer Biomark 3(6):315–324
9. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Dell’Era A, Bucciarelli P, Mannucci PM (2006) Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 44(6):1528–1534. doi:10.1002/hep.21435
10. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, Brancaccio V, Margaglione M (2007) The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 5(1):55–61. doi:10.1111/j.1538-7836.2006.02277.x
11. Orr DW, Patel RK, Lea NC, Westbrook RH, O’Grady JG, Heaton ND, Pagliuca A, Mufti GJ, Heneghan MA (2010) The prevalence of the activating JAK2 tyrosine kinase mutation in chronic porto-splenomesenteric venous thrombosis. Aliment Pharmacol Ther 31(12):1330–1336. doi:10.1111/j.1365-2036.2010.04299.x
12. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Sica S, Leone G (2007) Incidence of the JAK2 V617F mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 5(4):708–714. doi:10.1111/j.1538-7836.2007.02424.x
13. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111(10):4922–4929. doi:10.1182/blood-2007-11-125328
14. Bayraktar Y, Harmanci O, Buyukasik Y, Shorbagi AI, Sungur AH, Boylu CA, Gurgey A, Balkanci F (2008) JAK2V617F mutation in patients with portal vein thrombosis. Dig Dis Sci 53(10):2778–2783. doi:10.1007/s10620-008-0225-y
15. Qi X, Yang Z, Bai M, Shi X, Han G, Fan D (2011) Meta-analysis: the significance of screening for JAK2V617F mutation in Budd-Chiari syndrome and portal venous system thrombosis. Aliment Pharmacol Ther 33(10):1087–1103. doi:10.1111/j.1365-2036.2011.04627.x
16. Briere JB (2006) Budd-Chiari syndrome and portal vein thrombosis associated with myeloproliferative disorders: diagnosis and management. Semin Thromb Hemost 32(3):208–218. doi:10.1055/s-2006-939432
17. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Guilmin F, Kiladjian JJ, Plessier A, Denninger MH, Casadevall N, Valla D, Briere JB (2005) Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Brit J Haematol 129(4):553–560. doi:10.1111/j.1365-2141.2005.05490.x
18. Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96(3):450–453. doi:10.3324/haematol.2010.033191
19. Colaizzo D, Amitrano L, Guardascione MA, Balzano A, Margaglione M (2008) Janus kinase-2 mutation, cirrhosis and splanchnic vein thrombosis. Eur J Gastroenterol Hepatol 20(3):245–246. doi:10.1097/MEG.0b013e3282f1cff7
20. Xavier SG, Gadelha T, Pimenta G, Eugenio AM, Ribeiro DD, Gomes FM, Bonamino M, Zalcberg IR, Spector N (2010) JAK2V617F mutation in patients with splanchnic vein thrombosis. Dig Dis Sci 55(6):1770–1777. doi:10.1007/s10620-009-0933-y
21. Qi X, Zhang C, Han G, Zhang W, He C, Yin Z, Liu Z, Bai W, Li R, Bai M, Yang Z, Wu K, Fan D (2012) Prevalence of the JAK2V617F mutation in Chinese patients with Budd-Chiari syndrome and portal vein thrombosis: a prospective study. J Gastroenterol Hepatol 27(6):1036–1043. doi:10.1111/j.1440-1746.2011.07040.x
22. Franchini M (2012) Utility of testing for factor V Leiden. Blood Transfus 10(3):257–259. doi:10.2450/2012.0095-12
23. Rosendaal FR, Doggen CJ, Zivelin A, Arruda VR, Aiach M, Siscovick DS, Hillarp A, Watzke HH, Bernardi F, Cumming AM, Preston FE, Reitsma PH (1998) Geographic distribution of the 20210 G to A prothrombin variant. Thromb Haemost 79(4):706–708
24. Dentali F, Galli M, Gianni M, Ageno W (2008) Inherited thrombophilic abnormalities and risk of portal vein thrombosis. a meta-analysis. Thromb Haemost 99(4):675–682. doi:10.1160/TH07-08-0526
25. Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, Musha H, Takashi M, Suzuki N, Shinagawa T et al (1985) Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 89(2):279–286
26. Zocco MA, Di Stasio E, De Cristofaro R, Novi M, Ainora ME, Ponziani F, Riccardi L, Lancellotti S, Santoliquido A, Flore R, Pompili M, Rapaccini GL, Tondi P, Gasbarrini GB, Landolfi R, Gasbarrini A (2009) Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J Hepatol 51(4):682–689. doi:10.1016/j.jhep.2009.03.013